GC
AMAG

Guggenheim Capital’s AMAG Pharmaceuticals AMAG Stock Holding History

Guggenheim Capital’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-31,261
Closed -$380K – 2066
2019
Q4 		$380K Hold
31,261
– – ﹤0.01% 1714
2019
Q3 		$361K Sell
31,261
-512
-2% -$5.39K ﹤0.01% 1771
2019
Q2 		$317K Sell
31,773
-5
-0% -$54 ﹤0.01% 1846
2019
Q1 		$409K Buy
31,778
+156
+0.5% +$2.32K ﹤0.01% 1781
2018
Q4 		$480K Sell
31,622
-1,357
-4% -$25.9K ﹤0.01% 1702
2018
Q3 		$660K Buy
32,979
+155
+0.5% +$3.53K ﹤0.01% 1828
2018
Q2 		$640K Sell
32,824
-72,182
-69% -$1.6M ﹤0.01% 1816
2018
Q1 		$2.12M Sell
105,006
-29,924
-22% -$506K 0.01% 1592
2017
Q4 		$1.79M Sell
134,930
-52,427
-28% -$791K ﹤0.01% 1744
2017
Q3 		$3.46M Buy
187,357
+22,834
+14% +$426K 0.01% 1287
2017
Q2 		$3.03M Buy
164,523
+26,042
+19% +$516K 0.01% 1316
2017
Q1 		$3.12M Buy
138,481
+11,925
+9% +$285K 0.01% 1321
2016
Q4 		$4.4M Buy
126,556
+40,149
+46% +$1.2M 0.01% 1084
2016
Q3 		$2.12M Sell
86,407
-281
-0.3% -$7.02K 0.01% 1586
2016
Q2 		$2.07M Sell
86,688
-14,014
-14% -$321K 0.01% 1542
2016
Q1 		$2.36M Sell
100,702
-22,417
-18% -$532K 0.01% 1463
2015
Q4 		$3.72M Sell
123,119
-6,226
-5% -$201K 0.01% 1184
2015
Q3 		$5.14M Buy
129,345
+13,913
+12% +$864K 0.02% 1019
2015
Q2 		$7.97M Buy
115,432
+14,613
+14% +$919K 0.02% 943
2015
Q1 		$5.51M Buy
100,819
+26,323
+35% +$1.25M 0.01% 1123
2014
Q4 		$3.17M Sell
74,496
-13,613
-15% -$492K 0.01% 1388
2014
Q3 		$2.81M Buy
88,109
+17,178
+24% +$366K 0.01% 1522
2014
Q2 		$1.47M Buy
+70,931
New +$1.31M ﹤0.01% 2034

Other funds holding AMAG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Guggenheim Capital's AMAG Position: Q1 2020 in Review

Guggenheim Capital sold out of AMAG Pharmaceuticals (AMAG) in Q1 2020, closing a stake of 31,261 shares — an estimated $380K sold.

Guggenheim Capital first reported a position in AMAG in Q2 2014 and held it in 23 quarters. The position peaked at $7.97M in Q2 2015. 119 funds tracked by Wall St. Rank hold AMAG as of Q1 2020.

  • Guggenheim Capital reported no remaining AMAG Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Guggenheim Capital sold 31,261 AMAG Pharmaceuticals shares in Q1 2020, an estimated $380K.
  • Guggenheim Capital first reported a position in AMAG Pharmaceuticals in Q2 2014 and held it in 23 quarters.
  • Guggenheim Capital's AMAG Pharmaceuticals position peaked at $7.97M in Q2 2015.
  • 119 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q1 2020.

Based on Guggenheim Capital's 13F filing for Q1 2020, filed 2 Jun 2020.